Exclusive Networks Acquires Nuaware to Accelerate Cloud and DevOps Opportunities for Channel and Vendor Partners
Exclusive Networks today announced the acquisition of Nuaware, a hyper growth, born-in-the-cloud distributor at the bleeding edge of cloud, DevSecOps and containerisation. The move adds immediate global scale and services capability to the Nuaware proposition and portfolio, while enabling Exclusive Networks, its vendors and partner community with a unique skill set for capitalising on immense demand shifts brought about by digital transformation.
Jesper Trolle, CEO at Exclusive Networks said: "DevOps tool chains, containers and the emergence of DevSecOps are specialist areas where Nuaware has carved a truly unique niche in distribution. This acquisition puts us where we want to be in this space, giving our partners a readymade on-ramp into new high-growth opportunities. Large vendors being drawn to these markets are seeking turnkey channel solutions, and their established partner ecosystems have technical skills gaps that demand credible support. We can now meet these kinds of challenges far more effectively, while continuing to accelerate growth for the next waves of disruptive technologies in secure, trusted digital infrastructure.”
Nuaware was founded in 2016 by Zaheer Javaid and Luke Hasty and has grown exponentially since then through its work with vendors including HashiCorp, Docker Enterprise (now Mirantis), Instana, Portworx (recently acquired by Pure Storage) and Twistlock (now Palo Alto Networks Prisma Cloud). The company's London-based team, which works with both large service providers/systems integrators and a network of specialist DevOps consultancies on implementations around the world, will carry on operating as a distinct business unit under the Nuaware brand and continue to target disruptive new technologies and partnerships with emerging high-growth vendors such as, for example, Gremlin and StackPulse in areas such as chaos engineering and SRE automation. Its high-value services, including lead detection, business development, solution design, implementation, professional services and comprehensive training courses, will complement those from Exclusive Networks and vice versa.
Zaheer Javaid, Co-Founder and Director at Nuaware said: “We’re very pleased to be joining the Exclusive family and believe this is the best way to continue scaling up our proposition and bringing optimum value to all our customers and partners. The timing is right – the rapid onset of digital transformation among enterprises has got much faster in 2020, bringing Nuaware and the DevOps, cloud automation and containerisation technologies we specialise in, to an inflection point. With Exclusive’s support, we can aim higher, grow faster and invest more in extending our uniqueness in the market.”
“In terms of culture, attitude to innovation and the capacity to create unique value in the context of technology and market disruption, Nuaware is very much like Exclusive Networks,” said Andy Travers, EVP Worldwide Sales and Marketing at Exclusive Networks. “Teaming up this way is great news for partners of both companies, including the strategic vendors we have in common: Palo Alto Networks and Pure Storage. We anticipate significant organic growth from the Nuaware business by supporting its plans for continued expansion globally, and see many additional commercial benefits from extending their know-how across and into more opportunities with Exclusive Networks vendors and resellers.”
-ends-
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005189/en/
Contact information
Exclusive Networks Contact:
Jemma Lowman
Cohesive
+44 (0) 1291 626200
exclusivegroup@wearecohesive.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom